Oxycarboxin is a fungicide that acts as a systemic protectant against a wide range of fungal diseases in various crops. It is synthesized through a multi-step process involving reactions with 2-chloro-N-(2,6-dimethylphenyl)acetamide. Oxycarboxin is known for its efficacy in controlling diseases caused by basidiomycete fungi, particularly in cereals like wheat, barley, and oats. Its mechanism of action involves inhibiting the biosynthesis of ergosterol, a key component of fungal cell membranes, leading to fungal cell death. The importance of oxycarboxin lies in its broad-spectrum activity, its ability to protect crops from diseases, and its potential to improve crop yields. Research on oxycarboxin focuses on understanding its mode of action, optimizing its application, and evaluating its environmental impact. Studies are also conducted to explore its potential for developing new fungicides with enhanced efficacy and reduced environmental concerns.'
oxycarboxin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
oxycarboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-4,4-dioxo-1,4-oxathiine-3-carboxylic acid. A fungicide for the control of rust diseases on ornamentals, cereals and nursery trees as well as fairy rings on turf. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 21330 |
| CHEMBL ID | 1712057 |
| CHEBI ID | 7858 |
| SCHEMBL ID | 18897 |
| SCHEMBL ID | 22261885 |
| MeSH ID | M0052851 |
| Synonym |
|---|
| 1,4-oxathiin-3-carboxamide, 5,6-dihydro-2-methyl-n-phenyl-, 4,4-dioxide |
| wln: t6o dsw butj b1 cvmr |
| dcmod |
| vitavax sulfone |
| 2,4-oxathiin 4,4-dioxide |
| 1, 2,3-dihydro-5-carboxanilido-6-methyl-, 4,4-dioxide |
| oxicarboxin |
| oxycarboxine |
| plantvax |
| 1, 5,6-dihydro-2-methyl-, 4,4-dioxide |
| f461 |
| nsc232673 |
| 1, 5,6-dihydro-2-methyl-n-phenyl-, 4,4-dioxide |
| nsc-232673 |
| dioxide of vitavax |
| f 461 (pesticide) |
| carboxin sulfone |
| 5,4-oxathiin-3-carboxanilide 4,4-dioxide |
| vitavex |
| einecs 226-066-2 |
| 2,3-dihydro-6-methyl-5-phenylcarbamoyl-1,4-oxathiin 4,4-dioxide |
| f 461 (van) |
| oxycarboxin [ansi:bsi:iso] |
| plantvax 20 |
| 1,4-oxathiin, 2,3-dihydro-5-carboxanilido-6-methyl-, 4,4-dioxide |
| brn 1432554 |
| nsc 232673 |
| methyl-6 phenylcarbamoyl-5 dihydro-2,3 oxathiine-1,4-dioxyde-4,4 [french] |
| 5,6-dihydro-2-methyl-1,4-oxathi-ine-3-carboxanilide 4,4-dioxide |
| 5,6-dihydro-2-methyl-n-phenyl-1,4-oxathiin-3-carboxamide 4,4-dioxide |
| oxycarboxine [iso-french] |
| 5,6-dihydro-2-methyl-3-carboxanilido-1,4-oxathiin-4,4-dioxid [german] |
| caswell no. 627a |
| 1,4-oxathiin-3-carboxanilide, 5,6-dihydro-2-methyl-, 4,4-dioxide |
| 2,3-dihydro-5-carboxanilido-6-methyl-1,4-oxathiin, 4,4-dioxide |
| hsdb 1747 |
| 5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxanilide 4,4-dioxide |
| epa pesticide chemical code 090202 |
| oxycarboxin |
| 5259-88-1 |
| smr000461329 |
| n5-phenyl-6-methyl-4,4-dioxo-3,4-dihydro-2h-1,4lambda~6~-oxathiine-5-carboxamide |
| MLS000859552 |
| NCGC00163731-01 |
| MIXCOM1_000230 |
| MAYBRIDGE1_000120 |
| 6-methyl-4,4-dioxo-n-phenyl-2,3-dihydro-1,4-oxathiine-5-carboxamide |
| HMS2794D17 |
| dndi1729592 |
| chebi:7858 , |
| CHEMBL1712057 |
| dtxcid6014792 |
| cas-5259-88-1 |
| dtxsid8034792 , |
| NCGC00255599-01 |
| tox21_301331 |
| 2-methyl-n-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide 4,4-dioxide |
| dihydro-2-methyl-1,4-oxathiin-3-carboxanilide 4,4-dioxide |
| npu5gbn17x , |
| unii-npu5gbn17x |
| 5,6-dihydro-2-methyl-3-carboxanilido-1,4-oxathiin-4,4-dioxid |
| methyl-6 phenylcarbamoyl-5 dihydro-2,3 oxathiine-1,4-dioxyde-4,4 |
| AKOS015903489 |
| rendor |
| oxycarboxin [hsdb] |
| oxycarboxin [iso] |
| 5,6-dihydro-2-methyl-1,4-oxathiine-3-carboxanilide 4,4-dioxide |
| 2,3-dihydro-6-methyl-5-phenylcarbamoyl-1,4-oxathiine 4,4-dioxide |
| SCHEMBL18897 |
| plantvax 75 (salt/mix) |
| nsc 2322673 |
| oxathiin-3-carboxamide, 5,6-dihydro-2-methyl-n-phenyl-, 4,4-dioxide |
| oxathiin-3-carboxanilide, 5,6-dihydro-2-methyl-, 4,4-dioxide |
| 2,3-dihydro-5-carboxanilido-6-methyl-1,4-oxathiin 4,4-dioxide |
| AMEKQAFGQBKLKX-UHFFFAOYSA-N |
| 2-methyl-n-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide 4,4-dioxide # |
| dcmoo |
| oxykisvax |
| CCG-249571 |
| oxycarboxine, pestanal(r), analytical standard |
| 2-methyl-4,4-dioxo-n-phenyl-5,6-dihydro-1,4-oxathiine-3-carboxamide |
| carboxin sulfone m0 |
| carboxin tp2 |
| Q15965116 |
| SCHEMBL22261885 |
| Role | Description |
|---|---|
| EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor | An EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor that interferes with the action of succinate dehydrogenase (quinone), EC 1.3.5.1. |
| antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| sulfone | An organosulfur compound having the structure RS(=O)2R (R =/= H). |
| anilide | Any aromatic amide obtained by acylation of aniline. |
| oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
| organosulfur heterocyclic compound | |
| anilide fungicide | Any amide fungicide whose structure contains an anilide group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Nrf2 | Homo sapiens (human) | Potency | 28.1838 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 61.6146 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 24.4731 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 4.1493 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 41.1053 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 64.7941 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 63.0861 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 100.0000 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 49.5305 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 52.1508 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 20.1356 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 26.6747 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 46.1529 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 62.7236 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743079; AID743080; AID743091 |
| 67.9K protein | Vaccinia virus | Potency | 0.8428 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 38.8429 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID743212; AID743215; AID743227 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.6629 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 38.6139 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID588543; AID743222; AID743223; AID743241 |
| IDH1 | Homo sapiens (human) | Potency | 9.2000 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 48.5084 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 24.4731 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9141 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 18.6605 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| geminin | Homo sapiens (human) | Potency | 18.3564 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 48.5084 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 22.3872 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 20.4897 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 48.5084 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||